Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
roiv · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Roivant Sciences Ltd. (ROIV) measures how much investors pay for each dollar of the company's trailing earnings. ROIV's current PE ratio of N/A is calculated by dividing its stock price of $28.33 by its TTM earnings per share of -$0.43.
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2020 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Roivant Sciences Ltd.You ROIV | $20.4B | N/A | — | -$0.43 |
 Ascendis Pharma A/S ASND | $12.7B | N/A | — | -$3.61 |
 BridgeBio Pharma, Inc. BBIO | $13.2B | N/A | — | -$3.70 |
 Exact Sciences Corporation EXAS | $20.0B | N/A | — | -$1.10 |
 Ionis Pharmaceuticals, Inc. IONS | $12.2B | N/A | — | -$2.38 |
 Jazz Pharmaceuticals plc JAZZ | $15.0B | N/A | — | -$5.84 |
 Moderna, Inc. MRNA | $19.0B | N/A | — | -$7.25 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | — | $-0.43 | — | |
2025-03-31 FY2025 | — | $-0.24 | — | |
2024-03-31 FY2024 | 1.88x | $5.55 | — | |
2023-03-31 FY2023 | — | $-1.42 | — | |
2022-03-31 FY2022 | — | $-1.26 | — | |
2021-03-31 FY2021 | — | $-1.18 | — | |
2020-03-31 FY2020 | 5.93x | $1.75 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Roivant Sciences Ltd. (ROIV) measures how much investors pay for each dollar of the company's trailing earnings. ROIV's current PE ratio of N/A is calculated by dividing its stock price of $28.33 by its TTM earnings per share of -$0.43.
Frequently asked questions
ROIV pe ratio · 6 questionsROIV's current PE ratio is N/A as of 2026-06-08, based on a stock price of $28.33 and TTM EPS of -$0.43. Data sourced from Financial Modeling Prep via ROIV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Roivant Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08